[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"recurrent-meningioma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:recurrent-meningioma":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,42,70,93,117,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100249231","phase-2-vismodegib-fak-inhibitor-gsk2256098-capivasertib-and-abemaciclib-in-treating-patients-with-progressive-meningiomas-100249231",false,"NCT02523014","Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas","Phase II Trial of SMO\u002F AKT\u002F NF2\u002FCDK Inhibitors in Progressive Meningiomas With SMO\u002F AKT\u002F NF2\u002FCDK Pathway Mutations","* Documentation of disease:\n\n  * Histologic documentation: histologically proven intracranial meningioma as documented by central pathology review\n  * Molecular documentation: Presence of SMO, PTCH1, NF2, CDKN2A, AKT1, PIK3CA, PTEN mutations, CDKN2A copy number loss, CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain in tumor sample as documented specifically by the central laboratory, regardless of whether prior genotype testing outside of the central laboratory was performed\n  * Progressive OR residual disease, as defined by the following:\n\n    * Residual measurable disease: residual measurable disease immediately after surgery without requirement for progression; for grade I disease, progression pre-operatively needs to be documented, with an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 25 months; for patients with SMO\u002FPTCH1 mutations enrolling to receive vismodegib, the change can occur between scans separated by up to 25 months; residual measurable disease will be defined by bidimensionally measurable lesions with clearly defined margins by MRI scans, with a minimum diameter of 10 mm in both dimensions\n    * Progressive measurable disease: progression defined as an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 25 months\n    * Post radiation patients: patients with measurable and progressive meningioma who have received radiation are potentially eligible, but need to show evidence of progressive disease after completion of radiation; if the progressive meningioma lesion has been radiated, at least 24 weeks must have elapsed from completion of radiation to registration; if the progressive lesion is outside of the radiation field, then an interval of at least 2 weeks must have elapsed from completion of radiation to registration\n* Measurable disease: measurable disease is defined by a bidimensionally measurable main lesion on MRI or computed tomography (CT) images (MRI preferred) with clearly defined margins and a minimum diameter of 10 mm in both dimensions; multifocal disease is allowed\n* Prior treatment\n\n  * Prior medical therapy is allowed but not required\n  * No limit on number of prior therapies\n  * No chemotherapy, or other investigational agents within 28 days prior to registration\n  * No other concurrent investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study; additionally, no cases of nitrosourea or mitomycin C within 6 weeks prior to registration\n  * For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval \\> 4 weeks must have elapsed from completion of radiation therapy to registration; if the progressive lesion is outside of the radiation field, then an interval of at least 2 weeks must have elapsed from completion of radiation to registration\n  * Steroid dosing stable for at least 4 days\n  * Recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade 1 or less toxicity from other agents with exception of alopecia and fatigue\n  * No craniotomy 28 days prior to and after registration\n* Not pregnant and not nursing:\n\n  \\* A female of childbearing potential is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)\n* For patients with NF2\u002FCDKN2A\u002FAKT1\u002FPIK3CA\u002FPTEN mutation, CKDN2A copy number loss, or CDK4\u002FCDK6\u002FCCND1\u002FCCND2\u002FCCND3\u002FCCNE1 copy number gain: Age \\>= 18 years\n* For patients with SMO\u002FPTCH1 mutation: Age \\>= 30 years\n* Eastern Cooperative Oncology Group (ECOG) performance status =\\\u003C 2\n* Patient history:\n\n  * Patients with history of neurofibromatosis (NF) may have other stable central nervous system (CNS) tumors (schwannoma, acoustic neuroma or ependymoma) if lesions have been stable for 6 months\n  * No metastatic meningiomas (as defined by extracranial meningiomas outside of CNS) allowed; spinal meningiomas are allowed\n  * No history of allergic reactions attributed to compounds of similar or biologic composition to assigned study drug\n  * No known active hepatitis B or C\n  * No current Child Pugh class B or C liver disease\n  * No uncontrolled gastric ulcer disease (grade 3 gastric ulcer disease within 28 days of registration)\n  * No uncontrolled hypertension defined as blood pressure (BP) \\> 140\u002F90\n  * No abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 28 days prior to registration\n  * No major surgery within 28 days prior to registration for any patients with AKT1\u002FPIK3CA\u002FPTEN mutations receiving capivasertib\n  * For patients going on to receive capivasertib (i.e. enrolled after Update #08)\n\n    * Patients should not have any of the following cardiac criteria:\n\n      * Any clinically important abnormalities in rhythm, conduction, or morphology of resting electrocardiogram (EKG) (e.g., complete left bundle branch block, third degree heart block)\n      * Any factors that increase the risk of corrected QT (QTc) prolongation or risk of arrhythmic events such as heart failure, hypokalemia, potential for Torsade de Pointes, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval\n      * Experience any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure New York Heart Association (NYHA) class \\>= II\n      * Uncontrolled hypertension (systolic blood pressure \\[SBP\\] \\\u003C 90 mmHg and\u002For diastolic blood pressure \\[DBP\\] \\\u003C 50 mmHg)\n      * Cardiac ejection fraction outside institutional range of normal or \\\u003C 50% (whichever is higher) as measured by echocardiogram (or multigated acquisition \\[MUGA\\] scan if an echocardiogram can't be performed or is inconclusive); left ventricular ejection fraction (LVEF) below lower limit of normal for site\n    * Patients should not have any of the following criteria:\n\n      * With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of registration\n      * Hemoglobin \\\u003C 9 g\u002FdL (\\\u003C 5.59 mmol\u002FL); note: any blood transfusion must be \\>= 14 days prior to the determination of a hemoglobin \\>= 9 g\u002FdL (\\>= 5.59 mmol\u002FL)\n      * Proteinuria 3+ on dipstick analysis or \\> 500 mg\u002F24 hours\n      * Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of capivasertib\n      * History of hypersensitivity to active or inactive excipients of capivasertib or drugs with a similar chemical structure or class to capivasertib\n      * Current disease or condition known to interfere with absorption, distribution, metabolism, or excretion of drugs\n      * Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease\n      * Previous allogeneic bone marrow transplant\n      * Known immunodeficiency syndrome\n* Concomitant medications (only regarding NF2\u002FCDKN2A\u002FCDK4\u002FCDK6\u002FCCND1\u002FCCND2\u002FCCND3\u002FCCNE1\u002FAKT1\u002FPIK3CA\u002FPTEN genetic alterations):\n\n  * Chronic concomitant treatment with strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors must discontinue the drug for 14 days prior to registration on the study for patients with NF2 mutation enrolled to GSK2256098, as well as for patients with AKT1\u002FPIK3CA\u002FPTEN mutations enrolled to capivasertib\n  * For NF2 patients going on to receive GSK2256098 and for patients with AKT1\u002FPIK3CA\u002FPTEN mutations enrolled to capivasertib: concomitant treatment with strong CYP3A4 inducers or CYP2D6 substrates is not allowed; patients must discontinue the drug 14 days prior to registration\n  * For NF2 patients going on to receive abemaciclib: avoid concomitant use of CYP3A inducers and strong CYP3A inhibitors; use caution with coadministered moderate or weak CYP3A inhibitors\n* Diabetic status:\n\n  * For patients with NF2 or SMO\u002FPTCH1 mutations: No uncontrolled diabetes defined as a known diabetic with HBA1C \\> 7.5 OR fasting glucose \\> 140 mg\u002FdL.\n  * For patients with AKT1\u002FPIK3CA\u002FPTEN mutations:\n\n    * Glycosylated hemoglobin (HbA1C) \\\u003C 8.0% (63.9 mmol\u002Fmol)\n    * No type 1 diabetes mellitus\n    * No requirement for insulin for routine diabetic management and control\n    * No requirement for more than two oral hypoglycemic medications for routine diabetic management and control\n    * Patients with a pre-existing diagnosis of type 2 diabetes mellitus must have fasting glucose \\\u003C 9.3 mmol\u002FL (167mg\u002FdL); fasting is defined as no caloric intake for at least 8 hours\n  * Patients without a pre-existing diagnosis of type 2 diabetes mellitus must have fasting glucose =\\\u003C 7.0 mmol\u002FL (126 mg\u002FdL); fasting is defined as no caloric intake for at least 8 hours\n* Absolute neutrophil count (ANC) \\>= 1,500\u002Fmm\\^3\n* Platelet count \\>= 100,000\u002Fmm\\^3\n* Creatinine OR =\\\u003C 1.5 mg\u002Fdl x upper limit of normal (ULN) OR calculated (calc.) creatinine clearance \\> 50 mL\u002Fmin\n* Urine protein:creatinine ratio (UPC) =\\\u003C 45 mg\u002Fmmol\n* Total bilirubin =\\\u003C 1.5 x upper limit of normal (ULN); except in case of Gilbert's disease\n* Aspartate aminotransferase (AST)\u002Falanine aminotransferase (ALT) =\\\u003C 2.5 x ULN\n* Sodium, potassium, total calcium (corrected for serum albumin) \\& phosphorus within normal limits per institutional guidelines\n* QTcF \\\u003C 450 msec (QT calculated using Fridericia formula)\n* Mean resting heart rate (determined from EKG) 50-100 beats per minute (BMP) (must be obtained from 12-lead EKG defined by a triplicate EKG for patients assigned to the capivasertib arm; patients assigned to all other arms will require a single EKG\n* No uncontrolled medical comorbidities per investigator discretion (e.g. interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or pre-existing Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea)\n* ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: Hemoglobin \\>= 8 g\u002FdL\n\n  \\* Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier than the day after the erythrocyte transfusion\n* ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: Prior Treatment\n\n  * Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \\[CTCAE\\] grade =\\\u003C 1) from the acute effects of chemotherapy except for residual alopecia or grade 2 peripheral neuropathy prior to registration; a washout period of at least 28 days is required between last chemotherapy dose and registration (provided the patient did not receive radiotherapy)\n  * Patients who received adjuvant radiotherapy must have completed and fully recovered from the acute effects of radiotherapy; a washout period of at least 28 days is required between end of radiotherapy and registration\n* ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: No active bacterial infection (requiring intravenous \\[IV\\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \\[for example, hepatitis B surface antigen positive\\]); screening is not required for enrollment in the absence of symptoms\n* ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: No personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest","ALL","18 Years",{"count":19,"type":20},124,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.",[26,27,28],"Intracranial Meningioma","Recurrent Meningioma","NF2 Gene Mutation","RECRUITING","2026-07-01",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":33},"2015-09-28",{"date":37,"type":20},"2028-01",{"name":39,"class":40},"Alliance for Clinical Trials in Oncology","OTHER",780,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":69},"100541156","phase-2-177lu-dotatate-for-recurrent-meningioma-100541156","NCT06326190","177Lu-DOTATATE for Recurrent Meningioma","177Lu-DOTATATE for Recurrent Meningioma: a Randomized Phase II Study","LUMEN-1","Inclusion Criteria:\n\n* Adult patient ≥ 18 years of age\n* Histologically confirmed diagnosis of meningioma (all grades, 1-3 per WHO CNS5, are eligible)\n* WHO performance status 0-2\n* Measurable disease (at least 10 x10 mm contrast enhancing lesion) on cranial MRI no more than two weeks prior to randomization\n* Radiologically documented progression of any existing tumour (growth \\> 25% in the last two years) or appearance of new lesions (including intra- and extracranial manifestations)\n* Somatostatin receptor (SSTR)-positive confirmed by PET imaging with scan performed within four weeks before randomization (baseline SSTR-PET is considered as positive when meningioma uptake intensity exceeds a SUVmax of 2.3).\n* At least one prior surgery and one line of external beam radiotherapy for meningioma\n* Adequate liver, renal and haematological function within four weeks prior to randomization (1) Neutrophils ≥ 1.5 x 109\u002FL, hemoglobin ≥ 9 g\u002FdL or hemoglobin ≥ 5.6 mmol\u002FL, platelets ≥ 100 x 109\u002FL, (2) Total Bilirubin ≤ 1 x ULN, SGPT\u002FALT and SGOT\u002FAST ≤ 2.5 x ULN, (3) Albumin ≥ 30 g\u002FL, (4) Serum creatinine ≤ 1.5 x ULN, (5) Creatinine clearance \\> 40 ml\u002Fmin as calculated by CKD-EPI 2021\n* Participants must have the following electrolyte values within normal limits or corrected to be within normal limits with supplements prior to first dose of study medication: (1) Potassium (potassium level of up to 6.0 mmol\u002FL is acceptable at study entry if associated with creatinine clearance within normal limits calculated using CKD-EPI formula). Mild decrease below lower limit of normal (LLN) is acceptable at study entry if considered not clinically significant by investigator, (2) Magnesium, with the exception of magnesium level \\> ULN - 3.0 mg\u002FdL (1.23 mmol\u002FL) associated with creatinine clearance within normal limits calculated using CKD-EPI formula. Mild decrease below LLN is acceptable at study entry if considered not clinically significant by Investigator, (3) Total calcium (corrected for serum albumin) level of up to 12.5 mg\u002FdL (3.1 mmol\u002FL) is acceptable at study entry if associated with creatinine clearance within normal limits calculated using CKD-EPI formula. Mild decrease below LLN is acceptable at study entry if considered not clinically significant by Investigator.\n* Patients who are receiving corticosteroid treatment with dexamethasone, must be treated with a dose of ≤4 mg\u002Fday (or other corticosteroids equivalent dose) for a minimum of 7 days initiation of study treatment.\n* Women of childbearing potential (WOCBP) must have a negative serum (or urine) pregnancy test within 72 hours prior to randomization. A positive urine pregnancy test result must immediately be confirmed using a serum test. A pregnancy test is to be reported within 7 days prior to the first dose of the study treatment. Note: women of childbearing potential are defined as premenopausal females capable of becoming pregnant (i.e., females who have had any evidence of menses in the past 12 months, with the exception of those who had prior hysterectomy). However, women who have been amenorrhoeic for 12 or more months are still considered to be of childbearing potential if the amenorrhea is possibly due to prior chemotherapy, antioestrogens, low body weight, ovarian suppression, or other reasons.\n* Patients of childbearing \u002F reproductive potential should use adequate birth control measures during the study treatment period and for at least 6 months after the last dose of treatment. A highly effective method of birth control is defined as a method which results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly. Such methods include: (1) Combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal), (2) Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable), (3) Intrauterine device (IUD), (4) Intrauterine hormone-releasing system (IUS), (5) Bilateral tubal occlusion, (6) Vasectomized partner, (7) Sexual abstinence (the reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient)\n* Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 7 months after the last study treatment.\n* Before patient 's enrolment, written informed consent must be given according to ICH\u002FGCP, and national\u002Flocal regulations.\n\nExclusion Criteria:\n\n* Local therapy (surgery and \u002F or radiotherapy) indicated per local investigator. Note: in case of patients with multiple meningioma lesions, in whom resection and \u002F or radiotherapy of individual lesions is indicated, patients may be included after local therapy (with a 4-week gap between surgery \u002F end of radiotherapy and start of treatment), if at least one remaining lesion fulfils the inclusion criteria.\n* Any combined or any prior systemic treatment regardless the timing.\n* Life expectancy is less than nine weeks.\n* History of any other invasive malignancy within the last five years (except adequately treated non-melanoma skin cancer, clinically localized and very low-risk prostate cancer, and adequately treated cervical intraepithelial neoplasia)\n* Suspected pregnancy or when pregnancy has not been excluded\n* Contraindication to MRI, CT or PET\n* Unstable cardiac conditions (congestive heart failure, angina pectoris, myocardial infarction within one year before randomization, uncontrolled hypertension, clinically significant arrhythmias)\n* Psychological, familial, sociological, or geographical conditions potentially hamper compliance with the study protocol and follow-up schedule.\n* Known hypersensitivity to the active substance or to any excipients.",{"count":51,"type":20},136,[23],"Novel treatments are urgently needed for meningiomas progressing after local therapies (surgery, radiotherapy). So far, no effective systemic therapies are known in this situation. The LUMEN-1 trial will investigate in a prospective randomized trial the efficacy of the precision medicine \"theranostic\" concept of combining diagnostic patient selection using PET-based molecular imaging and target-specific therapeutic intervention using a systemically administered radioligand.\n\nThe rationale for the LUMEN-1 trial is based on the following: (a) high somatostatin receptor (SSTR) expression in meningiomas, (b) wide-spread availability of clinically established SSTR-PET imaging, (c) proven efficacy of SSTR-targeting radioligand therapy using \\[177Lu\\]Lu-DOTATATE in another tumor type (neuroendocrine tumors), and (d) promising experiences with \\[177Lu\\]Lu-DOTATATE therapy in compassionate use applications and retrospective case series and interim results from one ongoing uncontrolled prospective trial in meningiomas. LUMEN-1 is the first randomized clinical trial to investigate \\[177Lu\\]Lu-DOTATATE therapy in refractory meningioma and may open new avenues for treatment and research in this area.",[27],[56,57,27,58],"177Lu-DOTATATE","Meningioma","Phase II","2026-06-12",{"date":61,"type":33},"2026-06-15",{"date":63,"type":33},"2025-03-10",{"date":65,"type":20},"2028-12-22",{"name":67,"class":68},"European Organisation for Research and Treatment of Cancer - EORTC","NETWORK",19,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":21,"phases":79,"briefSummary":81,"conditions":82,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":92},"100604537","phase-1-ryz101-for-the-treatment-of-progressive-or-recurrent-intracranial-meningioma-100604537","NCT07150806","RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma","Progressive\u002FRecurrent Intracranial Meningioma Treated With SSTR-Targeted Alpha Emitter RYZ101 (PRIMe-STAR)","Inclusion Criteria:\n\n* Male or female patients of age \\> 18 years\n* Patients with 68Ga-DOTATATE positive recurrent or progressive meningiomas, any World Health Organization (WHO) grade, who have progressed after first line treatment.\n\n  * For Grade I meningioma, patients must have either:\n\n    * Progressive disease after at least surgical resection and radiotherapy, as defined as an increase in size of the measurable primary lesion (bidirectional area) on imaging by 25% or more between scans separated by no more than 12 months; or\n    * Progressive residual tumor after maximal safe resection, located at or near critical organs at-risk and considered to be high-risk for radiation injury by the treating investigator. Prior external beam radiotherapy is not required for these subjects.\n  * For Grade II or III meningioma, subjects must have either:\n\n    * Progressive disease after at least surgical resection and radiotherapy, as defined as an increase in size of the measurable primary lesion (bi-directional area) on imaging by 25% or more between scans separated by no more than 12 months or\n    * Residual measurable disease after prior surgery without requirement of progression, or\n    * Unsuitable for, or decline other standard of care treatment.\n* Positive 68Ga-DOTATATE uptake on PET\u002FCT at baseline, defined as target lesion uptake higher than the background with SUV ratios adjusted to the liver uptake (Krenning score ≥ 2)\n* Presence of measurable disease defined as at least one lesion measuring ≥ 5 mm in at least one dimension by contrast-enhanced MRI performed within 30 days prior to study registration\n* Multifocal disease allowed but limited to ≤ 3 measurable intracranial lesions on the most recent post-contrast MRI\n* There is no limit on the number of prior surgeries, radiation therapy, radiosurgery, systemically administered therapeutic agents or theranostic agents\n* For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval ≥ 24 weeks must have elapsed from completion from these therapies to registration unless there is histopathologic confirmation of recurrent tumor or there is new enhancing tumor outside the radiation field (beyond the high dose region or the 80% isodose line)\n* An interval of ≥ 28 days (or 5 half-lives, whichever is shorter) from prior cytotoxic chemotherapy (6 weeks from nitrosoureas), biologic agent, investigational agent or any other systemic agent prescribed for the purpose of treating meningioma\n* An interval of ≥ 28 days from craniotomy and ≥ 7 days from stereotactic biopsy\n* Patients must be willing and able to undergo regular MRI scans of the brain\n* Patients must have recovered to Common Terminology Criteria for Adverse Events (CTCAE) grade ≤ 1 or pretreatment baseline from clinically significant adverse events related to prior therapy (exclusions include alopecia, laboratory values listed per inclusion criteria, lymphopenia, sensory neuropathy ≤ grade 2, or other ≤ grade 2 not constituting a safety risk based on the investigator's judgment)\n* Any neurological symptoms must be stable for at least 28 days prior to enrollment and patients should not require escalating doses of steroids to control neurological symptoms (stable low dose maintenance steroids at ≤ 8 mg dexamethasone or equivalent are allowed)\n* Sufficient renal function, as evidenced by creatinine clearance (CrCl) ≥ 60 mL\u002Fmin calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation\n* Hemoglobin concentration ≥ 5.0 mmol\u002FL (≥ 8.0 g\u002FdL)\n\n  * Note: Colony-stimulating factors, platelet-production stimulators and\u002For transfusions within 4 weeks prior to screening and first dose of study treatment are not permitted to meet these criteria\n* Absolute neutrophil count (ANC) ≥ 1000 cells\u002FµL (≥ 1000 cells\u002Fmm\\^3)\n\n  * Note: Colony-stimulating factors, platelet-production stimulators and\u002For transfusions within 4 weeks prior to screening and first dose of study treatment are not permitted to meet these criteria.\n* Platelets \\> 100 × 10\\^9\u002FL (100 × 10\\^3\u002Fmm\\^3)\n\n  * Note: Colony-stimulating factors, platelet-production stimulators and\u002For transfusions within 4 weeks prior to screening and first dose of study treatment are not permitted to meet these criteria.\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN) (or ≤ 5 × ULN if presence of liver metastases)\n* Total bilirubin ≤ 3 × ULN\n* Serum albumin ≥ 3.0 g\u002FdL\n* Adequate coagulation function, defined by international normalized ratio (INR) or prothrombin time (PT) and activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN, unless subject is receiving anticoagulant therapy and PT or aPTT is within therapeutic range of intended use of anticoagulants\n* For women of childbearing potential (WOCBP):\n\n  * Negative pregnancy test within 48 hours prior to the first dose of study treatment\n  * Agreement to use barrier contraception and a second form of highly effective contraception while receiving study treatment and for 7 months following their last dose of study treatment. Alternatively, total abstinence is also considered a highly effective contraception method when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.\n\nA woman is considered to be of childbearing potential if she is postmenarche, has not reached a postmenopausal state (≥ 12 continuous months of amenorrhea \\[no menstrual bleeding of any kind, including menstrual period, irregular bleeding, spotting, etc.\\] with no identified cause other than menopause), and has not undergone surgical sterilization (total hysterectomy, or bilateral tubal ligation or bilateral oophorectomy at least 6 weeks before first dose of study treatment)\n\n* Sexually active male subjects must use a condom during intercourse while receiving RYZ101 and for at least 120 days after the last dose of the study treatment and should not father a child during this period.\n\n  * Male study subjects whose sexual partners are WOCBP must also agree to use a second form of highly effective contraception while receiving RYZ101 and for at least 4 months following their last dose. Alternatively, total abstinence is also considered a highly effective contraception method when this is in line with the preferred and usual lifestyle of the subject.\n  * Vasectomized men are also required to use a condom during intercourse, including with a male partner, to prevent delivery of the drug via seminal fluid.\n\nExclusion Criteria:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status \\> 2\n* Received radiation therapy to the brain in last 24 weeks\n* History of hypersensitivity or allergy to Actinium Ac-225 (225Ac), Gallium Ga 68 (68Ga), Copper Cu 64 (64Cu), octreotate, or any of the excipients of DOTATATE imaging agents\n* Prior radiopharmaceutical therapies (RPT), including radioembolization\n* Prior solid organ or bone marrow transplantation\n* Any toxicities from prior treatments that have not recovered to CTCAE grade ≤1, except for alopecia\n* Significant cardiovascular disease, defined as:\n\n  * New York Heart Association (NYHA) Class ≥ II heart failure.\n  * Known left ventricular ejection fraction (LVEF) \\\u003C 50%.\n  * History of myocardial infarction, acute coronary syndrome, or coronary angioplasty\u002Fstenting\u002Fbypass within the last 6 months.\n  * QT interval corrected for heart rate using Fridericia's formula (QTcF) \\> 470 ms, demonstrated by the average value of 3 consecutive electrocardiograms (ECGs).\n  * Resistant hypertension, defined as persistent uncontrolled blood pressure (BP) \\> 140\u002F90 mmHg while on optimal doses of at least 3 antihypertensive medications with 1 being a diuretic. Patients with baseline hypertension may be eligible after initiation of antihypertensive therapy\n* Uncontrolled diabetes mellitus as defined by hemoglobin A1C (HgB A1c) \\> 8% in patients with known diagnosis of diabetes mellitus)\n* Liver cirrhosis\n* Pregnancy or lactation\n* Unable to understand or unwilling to sign an Institutional review board approved written informed consent document\n* Current somatic or psychiatric disease\u002Fcondition that may interfere with the objectives and assessments of the study",{"count":78,"type":20},30,[80,23],"PHASE1","This phase I\u002FII tests the safety, side effects, best dose and how well giving RYZ101 works for the treatment of patients with intracranial meningioma that is growing, spreading, or getting worse (progressive) or that has come back after a period of improvement (recurrent). RYZ101 is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Giving RYZ101 may be safe, tolerable and\u002For effective in treating patients with progressive or recurrent intracranial meningioma.",[27],"2026-05-20",{"date":85,"type":33},"2026-05-22",{"date":87,"type":33},"2025-11-12",{"date":89,"type":20},"2026-12-31",{"name":91,"class":40},"Joshua Palmer",1,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":21,"phases":103,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":92},"100558929","adjuvant-hypofractionated-stereotactic-radiosurgery-for-intermediate-risk-meningioma-100558929","NCT06557512","Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma","A Pilot Trial of Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma (SRS-AIM)","SRS-AIM","Inclusion Criteria:\n\n* Age \\>+ 18 years at time of study entry\n* Ability to understand and the willingness to sign a written informed consent document.\n* Histologic diagnosis of newly diagnosed World Health Organization (WHO) grade 2 or recurrent WHO grade 1 meningioma. With regard to recurrent WHO grade 1 meningioma, participants must present with radiographic evidence of recurrence, and have a histologic diagnosis of WHO grade 1 meningioma at the most recent resection.\n\n  \\* Note: For participants diagnosed outside of University of California San Francisco (UCSF), re-review of pathology at UCSF is strongly encouraged. Hematoxylin and eosin (H\\&E) slides will be reviewed by UCSF pathologists.\n* Participants must have undergone a gross-total surgical resection as deemed by their neurosurgeon (Simpson grade I-III resection), using all available information which can include post-operative MRI, of a meningioma within 180 days of enrollment.\n* Participants must have a pre-operative MRI.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (Karnofsky score of 70 or higher)\n* Participants must have post-operative MRI indicating anatomy suitable for hypofractionated radiosurgery, as reviewed by the Radiation Oncology co-principal investigators (PIs).\n\nExclusion Criteria:\n\n* Concurrent participation in another clinical study with an investigational product unless it is an observational (non-interventional) study or the follow-up period of an interventional study.\n* Extensive multifocal (3 or more meningiomas) or metastatic disease.\n* Participants with tumors within 2mm of the optic apparatus or brainstem will be excluded.\n* Participants with another active primary malignancy or history of previous malignancy (except non-melanoma skin cancers, low and favourable-intermediate risk prostate cancers, and in situ cancers such as bladder, gastric, colon, cervical\u002Fdysplasia, or breast) are excluded unless a complete remission was achieved at least 2 years prior to study entry and no additional therapy is required or anticipated to be required during the study period.\n* Female participants who are pregnant.\n* Any underlying medical or psychiatric condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of participant safety or study results.\n* Participants with uncontrolled seizures, defined as greater than 3 disabling seizures per day while on anti-epileptic drugs.\n* Participants who have had previous intracranial radiotherapy overlapping with the area that would be targeted for stereotactic radiosurgery by this study.",{"count":102,"type":20},23,[104],"NA","This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back after a period of improvement (recurrent). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Hypofractionated stereotactic radiosurgery may be safe, tolerable, and effective in treating patients with grade II or recurrent grade I meningiomas after surgical resection.",[57,107,27],"Meningioma, Malignant","2026-05-14",{"date":110,"type":33},"2026-05-18",{"date":112,"type":33},"2024-12-13",{"date":114,"type":20},"2029-09-30",{"name":116,"class":40},"University of California, San Francisco",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":21,"phases":126,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":92},"100368838","phase-2-lutathera-for-the-treatment-of-inoperable-progressive-meningioma-after-external-beam-radiation-therapy-100368838","NCT04082520","Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy","A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy","Inclusion Criteria:\n\n* Previous treatment for meningioma including surgery, when possible, and radiation therapy (conventional fractionated or radiosurgery). Pathologic confirmation of meningioma is not required for patients who are not surgical candidates and received radiation therapy based on magnetic resonance imaging (MRI) consistent with meningioma. Patients with prior surgery will have pathologic confirmation of meningioma with either formalin-fixed paraffin-embedded (FFPE) tumor block OR meningioma tissue slides available for submission to central pathology review\n* Radiographic evidence of meningioma progression with measurable disease, defined as an increase in size of the measurable primary lesion on imaging by 15% or more (sum of the bidirectional measurements) in an approximate 6 month time period (i.e., calculated rate of growth 15% \u002F 6 months based on available scans) or by the appearance of a new measurable lesion\n* Previous treatment with either fractionated radiation therapy or stereotactic radiosurgery at the site of progressive meningioma, without safe option for further radiotherapy\n* Willing to undergo 68Ga-DOTATATE PET imaging. 68Ga-DOTATATE PET imaging must be Krenning score must be a score of 2 or higher, suggesting somatostatin receptor expression, to be registered on the study. A PET\u002FMRI is preferred, but PET\u002FCT is permitted if a patient is not technically able to receive a PET\u002FMRI or at the discretion of the primary investigator (PI).\n* Measurable disease\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) =\\\u003C 2\n* Absolute neutrophil count (ANC) \\>= 1500\u002Fmm (obtained =\\\u003C 28 days prior to registration)\n* Platelet count \\>= 100,000\u002Fmm (obtained =\\\u003C 28 days prior to registration)\n* Hemoglobin \\>= 9.0 g\u002FdL (obtained =\\\u003C 28 days prior to registration)\n* Direct bilirubin \\\u003C 1.5 x upper limit of normal (ULN) (or total bilirubin =\\\u003C 3.0 x ULN with direct bilirubin =\\\u003C 1.5 x ULN in patients with well-documented Gilbert's syndrome) (obtained =\\\u003C 28 days prior to registration)\n* Aspartate transaminase (AST) =\\\u003C 3 x ULN (obtained =\\\u003C 28 days prior to registration)\n* Prothrombin time (PT)\u002Finternational normalized ratio (INR)\u002Fpartial thromboplastin time (PTT) =\\\u003C 1.5 x ULN OR if patient is receiving anticoagulant therapy and PT or PTT is within therapeutic range of intended use of coagulants (obtained =\\\u003C 28 days prior to registration)\n* Calculated creatinine clearance must be \\>= 40 ml\u002Fmin using the Cockcroft-Gault formula (obtained =\\\u003C 28 days prior to registration) using the Chronic Kidney Disease Epidemiology Collaboration (CDK-EPI) equation.\n* Ability to complete questionnaire(s) by themselves or with assistance\n* Provide written informed consent\n* Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study) and it is highly recommend to see study staff in Radiation Oncology, Medical Oncology and\u002For Neuro-Oncology during the Event Monitoring Phase of the study.\n* Until 21 SPECT\u002FCT slots are filled, willing to undergo SPECT\u002FCT imaging for dosimetry analysis.\n\nExclusion Criteria:\n\n* Eligibility for surgical or radiation treatment with curative intent\n* Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant women (NOTE: Patients with surgical sterilization or who have been post-menopausal for at least 2 years are excluded form pregnancy testing, but this must be documented.)\n  * Nursing women\n  * Men or women of childbearing potential who are unwilling to employ adequate contraception\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Contraindications to or intolerance of MRI\n* Immunocompromised patients and patients known to be human immunodeficiency virus (HIV) positive and currently receiving antiretroviral therapy\n\n  * NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure (New York Heart Association \\[NYHA\\] II, III, IV), unstable angina pectoris, uncontrolled diabetes mellitus (fasting blood glucose \\> 2 ULN), cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm\n\n  * Note: This includes treatment with somatostatin LAR within 4 weeks prior to enrollment, or any patient receiving treatment with short-acting octreotide that cannot be interrupted for greater than 24 hours before treatment\n* Other active malignancy =\\\u003C 2 years prior to registration\n\n  * EXCEPTIONS: Non-melanotic skin cancer or carcinoma-in-situ of the cervix\n  * NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer\n* History of myocardial infarction =\\\u003C 6 months, or congestive heart failure requiring use of ongoing maintenance therapy for life-threatening ventricular arrhythmias\n* Current spontaneous urinary incontinence making impossible the safe administration of LUTATHERA\n* Untreated, refractory and\u002For symptomatic toxicity related to previous radiation therapy including radiation necrosis, radiation optic neuropathy, or radiation retinopathy\n* Optic nerve sheath meningioma, extracranial meningioma",{"count":125,"type":20},42,[23],"This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse (progressive) after external beam radiation therapy. Lutathera is a radioactive drug administered in the vein that is designed to target and kill tumor cells. The goal of this study is to determine whether this drug is safe and effective in treating meningiomas that progress after radiation treatment. WHO Grade I and Cohort WHO II\u002FIII cohorts will be evaluated.",[129,130,131,27,132],"Grade 1 Meningioma","Grade 2 Meningioma","Grade 3 Meningioma","Unresectable Meningioma","2026-04-17",{"date":135,"type":33},"2026-04-22",{"date":137,"type":33},"2020-04-14",{"date":139,"type":20},"2032-03-04",{"name":141,"class":40},"Mayo Clinic",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100274078","phase-2-optune-delivered-electric-field-therapy-and-bevacizumab-in-treating-patients-with-recurrent-or-progressive-grade-2-or-3-meningioma-100274078","NCT02847559","Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma","A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma","Inclusion Criteria:\n\n* Patients must have a histologic diagnosis of meningioma, World Health Organization (WHO) grade 2 or 3 (atypical or anaplastic)\n* Patient's tumor must have a supratentorial component\n* Patients must have measurable or non-measurable (evaluable) disease recurrence; recurrence must be documented by magnetic resonance imaging (MRI) or computed tomography (CT) scan\n* All patients must have developed recurrent disease\u002Fprogression (evidence of recurrence to be established by MRI or CT scan with contrast; there is no limit to the number of relapses) after receiving all standard treatments, which must include the following:\n\n  * Surgical resection, if possible;\n  * Definitive radiation therapy for unresectable meningioma, or for recurrent meningioma after resection (Note: At registration, patients must be at least 28 days post-surgery, and must be at least 28 days post-radiation therapy, with resolution of related cytotoxicities down to grade 2)\n* Patients may have had previous systemic treatment regimens with the exception of bevacizumab (no limit to number of prior therapies); a 4 week wash-out period prior to registration is mandatory for all systemic treatments\n* Life expectancy of at least 12 weeks\n* Karnofsky performance status \\>= 60%\n* Patients must have adequate bone marrow, kidney, and liver function, (within 14 days prior to registration), defined as:\n* Absolute neutrophil count (ANC) \\>= 1500\u002FuL (with\u002Fwithout growth factor)\n* Hemoglobin (Hgb) \\>= 9 g\u002FdL (with\u002Fwithout transfusion)\n* Platelets \\>= 100,000\u002FL\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\\u003C 2.5 x institutional upper limit of normal (ULN)\n* Total bilirubin =\\\u003C 1.5 x institutional ULN\n* Serum creatinine =\\\u003C 1.5 x institutional ULN\n* Females of child-bearing potential (FOCBP) and males with partners of childbearing potential must agree to use adequate contraception prior to study entry and for the duration of study treatment; should a female patient become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately; likewise, if the female partner of a male patient becomes pregnant or suspect she is pregnant, he should inform his treating physician immediately\n\nNOTE: A FOCBP is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n* Has not undergone a hysterectomy or bilateral oophorectomy\n* Has had menses at any time in the preceding 12 consecutive months (and therefore has not been naturally postmenopausal for \\> 12 months)\n\n  * FOCBP must have a negative serum or urine pregnancy test within 14 days prior to registration on study\n  * Patients must have the ability to understand and the willingness to sign a written informed consent prior to registration on study\n  * Patients must be able to comply with all protocol requirements\n\nExclusion Criteria:\n\n* Patients who have had major surgery or significant traumatic injury within 4 weeks prior to registration, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia), or patients that may require major surgery during the course of the study\n* Patients who have had minor surgical procedures (with the exception of the placement of porta cath or other central venous access) within 7 days prior to registration\n* Patients with infratentorial disease and spinal disease\n* Patients may not be receiving any other investigational agents; (i.e. 28-day washout period from prior investigational drug is required)\n* Patients may not receive any other anti-cancer therapies, within 28 days prior to registration and throughout the duration of this trial\n* Previous treatment with bevacizumab\n* Patients who have a history of allergic reactions attributed to compounds of similar chemical or biologic composition to bevacizumab are not eligible\n* Patients with active implanted medical device, a skull defect (such as, missing bone with no replacement), a shunt or bullet fragments; examples of active electronic devices include deep brain stimulators, spinal cord stimulators, vagus nerve stimulators, pacemakers, defibrillators, and programmable shunts\n* Patients with known sensitivity to conductive hydrogels like the gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes\n* Patients with proteinuria within 14 days of registration as demonstrated by either: urine protein creatinine (UPC) ratio \\>= 1.0 at screening OR urine dipstick for proteinuria 2+ (patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection, and must demonstrate =\\\u003C 1 g of protein\u002F24 hours to be eligible)\n* Patients with a serious non-healing wound, active ulcer, or untreated bone fracture\n* Patients with evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)\n* Patients with history of hematemesis or hemoptysis (defined as having bright red blood of 1\u002F2 teaspoon or more per episode) within 28 days prior to registration\n* History of myocardial infarction or unstable angina within 6 months of registration\n* Inadequately controlled hypertension (defined as systolic blood pressure \\> 150 mmHg and \u002For diastolic blood pressure \\> 100 mmHg)\n* History of stroke or transient ischemic attack within 6 months prior to registration\n* Any prior history of hypertensive crisis or hypertensive encephalopathy\n* History of abdominal fistula or gastrointestinal perforation within 6 months prior to registration\n* Chronic, systemic treatment with immunosuppressive agents; patients who require a stable dose of corticosteroids for control of cerebral edema are eligible; topical or inhaled steroids are also allowed\n* Patients who have any severe and\u002For uncontrolled intercurrent medical conditions including, but not limited to any of the following, are not eligible:\n\n  * Ongoing or active wound infection requiring concurrent systemic antibiotic treatment; there is no mandatory duration of time that a patient has to be off antibiotics, but the treating physician has to deem the infection as effectively treated prior to enrollment\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia (New York Heart Association \\[NYHA\\] criteria)\n  * Psychiatric illness\u002Fsocial situations that would limit compliance with study requirements, prevent patient comprehension of the nature of, and risk associated with, the study\n  * Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints\n* Female patients who are pregnant or nursing are not eligible",{"count":150,"type":20},27,[23],"The purpose of this research study is to determine the effects bevacizumab (the study drug) combined with Optune (the study device) tumor treatment field therapy has on meningiomas. Bevacizumab is considered investigational because the US Food and Drug Administration (FDA) has not approved its use for the treatment of meningiomas. The study drug is a medication that blocks the growth of new blood vessels. It is thought that the study drug may interfere with the growth of new blood vessels and therefore might stop tumor growth, and possibly shrink the tumor by keeping it from receiving nutrients and oxygen supplied by the blood vessels. Optune is also considered investigational because the US FDA has not approved its use for the treatment of meningiomas. Optune is a device that the patient will wear and use for at least 18 hours of each day. It delivers alternating electrical current to the patient's brain tumor and by doing so interrupts a process called mitosis. Mitosis needs to occur in order for cell division to occur and allows tumors to grow. By slowing this process, we hypothesize that meningioma growth may also be slowed.",[154,155,156,157,27,158],"Anaplastic (Malignant) Meningioma","Atypical Meningioma","Grade II Meningioma","Grade III Meningioma","Supratentorial Meningioma","2025-06-25",{"date":161,"type":33},"2025-06-27",{"date":163,"type":33},"2016-08-01",{"date":165,"type":20},"2026-12",{"name":167,"class":40},"Northwestern University",8]